Original artcle here.
Here we respond to some of the points made in Jane Hansen’s article where she strongly implies that Bexsero should be placed on the NIP schedule.
1. “The vaccine Bexsero has been rejected for the fourth time by the Pharmaceutical Benefits Advisory Committee, which cited cost as the main reason.”
The above statement is materially inaccurate. In fact, the most substantive reasons the PBAC gave for its decision to reject all four of GSK’s applications to have their Bexsero vaccine included on the schedule was that the manufacturer, even after repeated requests by the Advisory Committee, could not provide any evidence that this vaccine was effective or provided any herd immunity…. [Read More]